- Active, not recruiting
NCT03556332: Phase 2 - Carfilzomib, Lenalidomide, Dex Daratumumab for relap. MM with auto transplant
Updated: Feb 10
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Dara-KRd
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborator
Janssen Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03556332
Official Title: Phase 2 Trial of Intensive Chemo-immunotherapy With Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation
First Posted : June 14, 2018
Click here for details on ClinicalTrials.gov
* Carfilzomib (Kyprolis)
* Lenalidomide (Revlimid)
* Dexamethasone (Decadron)
* Daratumumab (Darzalex)
- New York: Memorial Sloan-Kettering Cancer Center New York
- Alabama: University of Alabama at Birmingham
Locations
United States, Alabama
United States, New Jersey
United States, New York
United States, North Carolina
United States, Wisconsin